| screen_phc_ke | n | percent |
|---|---|---|
| Rhodes | 889 | 53.9% |
| Karen | 431 | 26.2% |
| Riruta | 328 | 19.9% |
| Total | 1648 | 100.0% |
Participants Gender & Site Data
| screen_phc_ke | Female | Male |
|---|---|---|
| Rhodes | 41.8% (372) | 58.2% (517) |
| Karen | 54.8% (236) | 45.2% (195) |
| Riruta | 62.8% (206) | 37.2% (122) |
| Total | 49.4% (814) | 50.6% (834) |
The table below show the total number of participnats screened this week
| screen_phc_ke | n | percent |
|---|---|---|
| Rhodes | 22 | 46.8% |
| Karen | 12 | 25.5% |
| Riruta | 13 | 27.7% |
| Total | 47 | 100.0% |
Screening Eligibility
| screen_eligible_conf | Rhodes | Karen | Riruta | Total |
|---|---|---|---|---|
| Yes | 193 | 132 | 125 | 450 |
| No | 696 | 299 | 203 | 1198 |
The table below show the total number of participants screened, eligible and those not eligible this week
| screen_eligible_conf | Rhodes | Karen | Riruta | Total |
|---|---|---|---|---|
| Yes | 9 | 6 | 10 | 25 |
| No | 13 | 6 | 3 | 22 |
ELigible and Consented partcipants
| screen_consent_yn | Rhodes | Karen | Riruta | Total |
|---|---|---|---|---|
| Yes | 193 | 123 | 116 | 432 |
| No | 1 | 9 | 48 | 58 |
| NA | 695 | 299 | 164 | 1158 |
Removed all NAs from the data above
| screened$screen_consent_yn | n | percent |
|---|---|---|
| Yes | 432 | 88.2% |
| No | 58 | 11.8% |
| Total | 490 | - |
The table below show the total number of participnats consented to the study this week
| screen_consent_yn | Rhodes | Karen | Riruta | Total |
|---|---|---|---|---|
| Yes | 9 | 6 | 10 | 25 |
| No | 0 | 0 | 2 | 2 |
| NA | 13 | 6 | 1 | 20 |
| enrol_phc_ke | Jun 2025 | Jul 2025 | Aug 2025 | Sept 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Karen | 27 | 25 | 9 | 11 | 10 | 8 | 3 | 4 | 14 | 12 | 123 |
| Rhodes | 14 | 38 | 19 | 21 | 17 | 12 | 12 | 12 | 29 | 19 | 193 |
| Riruta | 0 | 0 | 0 | 14 | 11 | 12 | 2 | 4 | 50 | 23 | 116 |
| Total | 41 | 63 | 28 | 46 | 38 | 32 | 17 | 20 | 93 | 54 | 432 |
| enrol_phc_ke | Positive | Negative | Trace | Indeterminate | No sputum | NA_ |
|---|---|---|---|---|---|---|
| Rhodes | 93 | 99 | 0 | 0 | 0 | 1 |
| Karen | 4 | 113 | 0 | 0 | 6 | 0 |
| Riruta | 17 | 98 | 0 | 0 | 1 | 0 |
| Total | 114 | 310 | 0 | 0 | 7 | 1 |
| xpert_result | n | percent | valid_percent |
|---|---|---|---|
| Positive | 114 | 26% | 26% |
| Negative | 310 | 72% | 72% |
| Trace | 0 | 0% | 0% |
| Indeterminate | 0 | 0% | 0% |
| No sputum | 7 | 2% | 2% |
| NA | 1 | 0% | - |
| Total | 432 | - | - |
| Positive | Negative | Trace | Indeterminate | No sputum | NA_ |
|---|---|---|---|---|---|
| Rhodes | |||||
| 48.2% (93) | 51.3% (99) | 0.0% (0) | 0.0% (0) | 0.0% (0) | 0.5% (1) |
| Karen | |||||
| 3.3% (4) | 91.9% (113) | 0.0% (0) | 0.0% (0) | 4.9% (6) | 0.0% (0) |
| Riruta | |||||
| 14.7% (17) | 84.5% (98) | 0.0% (0) | 0.0% (0) | 0.9% (1) | 0.0% (0) |
| Total | |||||
| 26.4% (114) | 71.8% (310) | 0.0% (0) | 0.0% (0) | 1.6% (7) | 0.2% (1) |
| enrol_phc_ke | n | percent |
|---|---|---|
| Rhodes | 193 | 40.0% |
| Karen | 123 | 30.0% |
| Riruta | 116 | 30.0% |
| Total | 432 | 100.0% |
| enrol_phc_ke | n | percent |
|---|---|---|
| Rhodes | 9 | 36.0% |
| Karen | 6 | 24.0% |
| Riruta | 10 | 40.0% |
| Total | 25 | 100.0% |
| obs_phc_ke | n | percent |
|---|---|---|
| Rhodes | 90 | 31.1% |
| Karen | 103 | 35.6% |
| Riruta | 96 | 33.2% |
| Total | 289 | 100.0% |
| obs_phc_ke | n | percent |
|---|---|---|
| Rhodes | 2 | 11.1% |
| Karen | 6 | 33.3% |
| Riruta | 10 | 55.6% |
| Total | 18 | 100.0% |
| obs_phc_ke | Jun 2025 | Jul 2025 | Aug 2025 | Sept 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Karen | 12 | 24 | 10 | 6 | 11 | 7 | 3 | 4 | 14 | 12 | 103 |
| Rhodes | 6 | 19 | 7 | 11 | 13 | 2 | 3 | 8 | 15 | 6 | 90 |
| Riruta | 0 | 0 | 0 | 6 | 12 | 5 | 3 | 2 | 49 | 19 | 96 |
| Total | 18 | 43 | 17 | 23 | 36 | 14 | 9 | 14 | 78 | 37 | 289 |
| obs_phc_ke | n |
|---|---|
| Rhodes | 24 |
| Karen | 35 |
| Total | 59 |
| obs_phc_ke | n |
|---|---|
| Rhodes | 2 |
| Karen | 2 |
| Total | 4 |
| exit_reason | n |
|---|---|
| Completed all follow up (26 week visit and MGIT result feedback) | 24 |
| Study withdrawal | 7 |
| Lost to follow up (missed visit procedures completed) | 6 |
| Notified of participant death | 5 |
| Other | 22 |
| No longer eligible (baseline Xpert positive) | 102 |
| No longer eligible (baseline MGIT positive) | 7 |
| Total | 173 |
| exit_reason | exit_reason_detail | n |
|---|---|---|
| Other | Failed to attend study visit within stipulated timeline | 1 |
| Other | LAM positive results | 1 |
| Other | LAM positive results | 1 |
| Other | Missed baselines cohort visit within study window | 1 |
| Other | Out of window period | 3 |
| Other | Outside the window period | 1 |
| Other | Outside the window period | 7 |
| Other | Outside window period | 1 |
| Other | Outside window period | 1 |
| Other | Participant could not attend the baseline cohort visit within the study window | 1 |
| Other | Participant realised she was pregnant | 1 |
| Other | Participant urine lam turned positive | 1 |
| Other | Participant was not feeling well during the window period of cohort enrollment | 1 |
| Other | Work related matters | 1 |
| Total | - | 22 |
| exit_reason | n | percent |
|---|---|---|
| Completed all follow up (26 week visit and MGIT result feedback) | 24 | 52.2% |
| Study withdrawal | 1 | 2.2% |
| Lost to follow up (missed visit procedures completed) | 6 | 13.0% |
| Notified of participant death | 5 | 10.9% |
| Other | 3 | 6.5% |
| No longer eligible (baseline Xpert positive) | 0 | 0.0% |
| Not selected for cohort | 0 | 0.0% |
| No longer eligible (baseline MGIT positive) | 7 | 15.2% |
| Total | 46 | 100.0% |
| exit_reason | exit_reason_detail | n |
|---|---|---|
| Other | LAM positive results | 1 |
| Other | LAM positive results | 1 |
| Other | Participant urine lam turned positive | 1 |
| Total | - | 3 |
| obs_phc_ke | n |
|---|---|
| Rhodes | 79 |
| Karen | 70 |
| Riruta | 94 |
| Total | 243 |